Oncternal Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCT research report →
About the company
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating cancer treatments for diseases where current medical options are insufficient. Its clinical-stage portfolio features zilovertamab, a humanized monoclonal antibody designed to bind to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule that works by inhibiting the biological activity of ETS-family transcription factor oncoproteins.
- CEO
- James B. Breitmeyer
- IPO
- 2004
- Employees
- 27
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $1.56M
- P/E
- -0.04
- P/S
- 1.99
- P/B
- 0.05
- EV/EBITDA
- -2.16
- Div Yield
- 0.00%
- Gross Margin
- -3690.19%
- Op Margin
- -5313.89%
- Net Margin
- -5029.17%
- ROE
- 61.57%
- ROIC
- -131.57%
- Revenue
- $785.00K · -47.32%
- Net Income
- $-39,479,000 · 9.02%
- EPS
- $-13.43 · 18.61%
- Op Income
- $-41,714,000
- FCF YoY
- 12.37%
- 52W High
- $10.61
- 52W Low
- $0.53
- 50D MA
- $0.53
- 200D MA
- $3.80
- Beta
- 1.36
- Avg Volume
- 62.27K
Get TickerSpark's AI analysis on ONCT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 20, 24 | KISNER DANIEL L | other | 2,200 |
| Jun 20, 24 | CARTER MICHAEL G | other | 2,200 |
| Jun 20, 24 | Wills Robert James | other | 2,200 |
| Jun 20, 24 | LARUE WILLIAM R | other | 2,200 |
| Jun 20, 24 | HALE DAVID F | other | 3,300 |
| Jun 20, 24 | MAZANET ROSEMARY | other | 2,200 |
| Jun 20, 24 | THEUER CHARLES | other | 2,200 |
| Jun 20, 24 | DeSimone Jill | other | 2,200 |
| Apr 8, 24 | Wills Robert James | buy | 3,086 |
| Mar 28, 24 | Wills Robert James | buy | 6,914 |
Our ONCT coverage
Recent articles, reports, and earnings notes.
No research on ONCT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONCT report →Similar companies
Peers in the same neighborhood.